Previous Article | Next Article ![]()
Journal of Bacteriology, May 2007, p. 3635-3638, Vol. 189, No. 9
0021-9193/07/$08.00+0 doi:10.1128/JB.01757-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892,1 Department of Biological Sciences, Duquesne University, Pittsburgh, Pennsylvania 152822
Received 16 November 2006/ Accepted 19 February 2007
|
|
|---|
|
|
|---|
In addition to DnaJ, Escherichia coli contains five other DnaJ homologs, including CbpA (curved DNA-binding protein A), which was first identified as a DNA-binding protein (15). CbpA binds DNA efficiently, with a preference for curved DNA, and has been localized to the nucleoids of stationary-phase cells (1, 8, 15). CbpA differs from DnaJ in that it is a type II DnaJ protein, lacking the zinc-binding domain characteristic of E. coli DnaJ and other type I DnaJ proteins. High-level expression of CbpA suppresses several phenotypes associated with dnaJ deletions, including temperature sensitivity and
replication defects (15).
The cbpA gene is in an operon that has a
S-dependent promoter (17). Another gene, cbpM (CbpA modulator), lies downstream of cbpA within the same operon (4). cbpM encodes an 11-kDa protein that has structural homology to DafA of Thermus thermophilus (4). DafATth (DnaK assembly factor A) mediates the assembly of ring-like structures composed of a trimer each of DnaKTth, DnaJTth, and DafATth (13), and this complex is proposed to hold the DnaK chaperone system in an inactive state (5, 11). E. coli CbpM can bind to and inhibit CbpA in vitro, but it has not been shown to interact with DnaK (2, 4).
Here, we have examined the relationship between CbpA and CbpM within the cell. We discovered that CbpM specifically inhibits the in vivo activity of CbpA. Moreover, CbpM forms a stable complex with CbpA in vivo. This suggests that the interaction between CbpM and CbpA results in the inhibition of CbpA activity. These results demonstrate that the in vivo activity of the E. coli DnaK chaperone system can be modulated by CbpM.
CbpM specifically inhibits CbpA function in vivo.
To study the in vivo activities of CbpA and CbpM, we used the strains listed in Table 1. All strains used were derivatives of BW27784, a derivative of MG1655 (10), and transductions with P1vir were performed as described previously (12). Deletion/insertion mutations in cbpA, cbpM, and cbpAM were created as described previously (18), using chloramphenicol resistance cassettes that were amplified using the oligonucleotide primer pairs listed in Table 2. The
cbpA3 deletion removed bases 1 to 840 of cbpA, leaving the last 81 nucleotides. The
cbpM3 deletion removed bases 2 to 306 of cbpM. The
cbpAM3 deletion removed all DNA between the cbpA ATG start codon and the cbpM TGA stop codon. Mutations were confirmed by sequencing. Except as indicated for specific experiments, all strains were cultured at 30°C prior to experimental use, excluding
dnaJ
cbpAM3 mutants, which were cultured at 25°C.
|
View this table: [in a new window] |
TABLE 1. Strains and plasmids utilized in this study
|
|
View this table: [in a new window] |
TABLE 2. Oligonucleotides used for plasmid and strain construction
|
dnaJ
cbpA strains (16). The observation that CbpA can functionally compensate for DnaJ allowed us to test whether CbpM, expressed from a multicopy plasmid, inhibits the function of CbpA in vivo. We constructed the pcbpA+ and pcbpM+ plasmids by amplifying cbpA and cbpM by PCR using the oligonucleotide primers indicated in Table 2. cbpA was digested with EcoRI and HindIII and cbpM with NcoI and HindIII. The inserts were ligated into pBAD24 (9), electroporated into DH5
, purified, sequenced, and electroporated into the BW27784 derivatives. We then expressed CbpM from the plasmid in various deletion strains and measured growth over a range of temperatures.
We first tested the deletion strains for their abilities to grow in the absence of pcbpM+. Strains with single deletions of dnaJ, double deletions of cbpAM, or triple deletions of dnaJ and cbpAM were grown at 25°C and plated at 16°C, 25°C, 30°C, and 37°C. As expected, the parental (Fig. 1, column 1) and
dnaJ (Fig. 1, column 3) strains grew well at all temperatures tested. Likewise, the
cbpAM3 (Fig. 1, column 2),
cbpA3 (data not shown), and
cbpM3 (data not shown) strains grew well under the conditions tested. In contrast, growth of the triple deletion strain that lacked dnaJ, cbpA, and cbpM was reduced about 10,000-fold at 16°C and 37°C (Fig. 1, column 4). At 25°C and 30°C, growth of the
dnaJ
cbpAM3 strain was reduced about 100-fold (Fig. 1, column 4). When pcbpM+ was introduced into a
dnaJ cbpAM+ strain and subsequently induced with arabinose at 16° and 37°C, there was a dramatic reduction of growth by about 10,000-fold (Fig. 1, column 6). At 25°C, there was no apparent effect on growth by induction of cbpM from the plasmid, while there was a small effect at 30°C (Fig. 1, column 6). The growth defects caused by high-level expression of CbpM in the
dnaJ cbpAM+ strain were very similar to those for the phenotypes of the
dnaJ
cbpAM3 mutant, suggesting that CbpM was inhibiting CbpA.
dnaJ cbpAM+ mutant cells carrying the pcbpM+ plasmid but not induced with arabinose exhibited decreased growth at 16°C and 37°C (about threefold lower than that of the vector-only control), indicating that low-level expression of CbpM was sufficient to elicit the growth defect (data not shown). In a control experiment in which pcbpM+ was present in the
dnaJ cbpAM+ strain but repressed by the addition of glucose to the medium, there was no inhibition of growth at 16°C or 37°C (Fig. 1, column 9). The vector alone did not inhibit the growth of
dnaJ cbpAM+ cells at any temperature in the presence of arabinose or glucose (Fig. 1, columns 5 and 8). Interestingly, induction of pcbpM+ by arabinose in the dnaJ+ cells did not inhibit growth at a high or low temperature, suggesting that CbpM does not inhibit DnaJ in vivo (Fig. 1, column 7). Overexpression of CbpM in dnaJ+
cbpAM or
dnaJ
cbpAM strains had no significant effect on growth (data not shown), demonstrating that other DnaJ homologs were not inhibited by CbpM. Taken together, these data demonstrate for the first time that CbpM is able to specifically inhibit CbpA function in vivo.
![]() View larger version (67K): [in a new window] |
FIG. 1. Growth of dnaJ and cbpAM3 strains at different temperatures and the effects of CbpM overexpression. E. coli strains with the indicated dnaJ and cbpAM genotypes were grown for 24 h at 25°C and then serially diluted in LB. Ten microliters of the indicated dilutions was spotted on LB agar (plus 100 µg/ml ampicillin for strains containing plasmids) and incubated at the indicated temperatures for 24 h (30°C and 37°C), 48 h (25°C), or 96 h (16°C). Strains marked "V" contained the empty pBAD24 vector. Strains marked "M" contained the pcbpM+ construct. Arabinose (0.02%) or glucose (0.5%) was added to the culture medium for strains bearing plasmids as indicated.
|
dnaJ
cbpA strain is defective in cell division, forming long filamentous cells (16). We wanted to determine whether high-level expression of CbpM could also cause a similar cell division defect in the
dnaJ cbpAM+ mutant. Cells were grown to late stationary phase at 25°C and examined by phase-contrast microscopy. We observed that the wild-type,
cbpA3,
dnaJ,
cbpM3, and
cbpAM3 strains all exhibited small, rod-shaped cells (Fig. 2A and data not shown). However, the
dnaJ
cbpAM triple mutant displayed a filamentous morphology (Fig. 2A) similar to that described for the
dnaJ
cbpA double mutant (16). Complementation of the
dnaJ
cbpAM3 strain with pcbpA+ reverted the cells to wild-type morphology, showing that CbpA activity in
dnaJ cells is necessary for proper cell division and that CbpM activity is dispensable (Fig. 2A). To determine whether the function of CbpA in cell division could be inhibited by CbpM, pcbpM+ was introduced into a
dnaJ strain and induced with arabinose. High-level expression of CbpM resulted in filamentous cells (Fig. 2A), suggesting that CbpM was able to counteract CbpA activity, yielding a
dnaJ
cbpA phenocopy. Expression of CbpM in a
cbpA dnaJ+ strain did not result in filamentous cells, indicating that CbpM was not able to inhibit DnaJ (Fig. 2A).
![]() View larger version (30K): [in a new window] |
FIG. 2. Cellular morphology of wild-type (WT), cbpA3, dnaJ, and dnaJ cbpAM3 strains and the effects of CbpA and CbpM overexpression. Strains were grown for 24 h at 25°C in LB and then examined by either phase-contrast (A) or fluorescent (B) microscopy. The relevant strain genotypes are indicated to the left of the figure, and strains bearing plasmids were grown in the presence of arabinose (0.02%) and ampicillin (100 µg/ml).
|
dnaJ
cbpA double mutants are known to be defective in septum formation (16). To determine the nature of the cell division defect seen in
dnaJ cells expressing high levels of CbpM, the DNA was stained with a fluorescent dye, Hoechs 33342 (Invitrogen), and nucleoid localization was examined by fluorescent microscopy using a Zeiss 510 NLO microscope as previously described (6). In the
dnaJ cbpAM+ cells expressing additional cbpM from a plasmid, discrete nucleoids were visible throughout the lengths of the filaments, indicating that the activity missing from the cells participates in septum formation, not chromosome segregation (Fig. 2B). Taken together, the restricted growth temperature and the altered cellular morphology demonstrate that CbpM is capable of inhibiting CbpA in vivo.
In vivo interaction of CbpA and CbpM.
To determine whether CbpA and CbpM physically interact in vivo, we probed for a potential intermolecular interaction using coimmunoprecipitation. Wild-type and
cbpA3 strains were grown to early stationary phase (optical density at 595 nm of 3.0, 7 h of growth), and clarified cell lysates were incubated with polyclonal antibodies raised against CbpA. Antibody-protein complexes were precipitated with protein A-Sepharose (Amersham). The immunoprecipitated material was subjected to Western blot analysis using CbpM antiserum (Fig. 3A). The results revealed that significant amounts of CbpM were precipitated from the wild-type lysate with CbpA antiserum (Fig. 3A, lane 4) but not from the
cbpA3 lysate (Fig. 3B, lane 4). Lysates from late-stationary-phase wild-type cells (optical density at 595 nm of 5.0, 24 h of growth) were immunoprecipitated with CbpA, CbpM, or one of several other antisera, followed by Western blot analysis for detection of CbpM. CbpM again specifically coprecipitated with CbpA antiserum (Fig. 3C, lane 1) and also with CbpM antiserum as expected (Fig. 3C, lane 2). In control experiments, CbpM-containing complexes were not detected in significant amounts when preimmune serum or antiserum raised against other proteins (ClpB, ClpA, ClpP, and
S) was used for the immunoprecipitation (Fig. 3C, lanes 3 to 7). These results demonstrate that CbpA and CbpM form a complex in both early- and late-stationary-phase cells. They do not rule out the possibility that CbpA and CbpM are also associated with other proteins. The results suggest that it is the complex of CbpA and CbpM that results in the inhibition of CbpA in vivo.
![]() View larger version (62K): [in a new window] |
FIG. 3. Coimmunoprecipitation of CbpA and CbpM. (A) Coimmunoprecipitation was performed on early-stationary-phase wild-type cells by utilizing CbpA antibodies. Fractions from the procedure were analyzed for CbpM content by Western blotting with CbpM antibodies, using a WesternBreeze kit (Invitrogen). Lane 1, total cellular protein; lane 2, clarified lysate; lane 3, final wash of immunoprecipitate; lane 4; immunoprecipitate; lane M, purified CbpM. (B) Coimmunoprecipitation was performed on early-stationary-phase cbpA3 cells by utilizing CbpA antibodies as described for Fig. 3A. (C) Coimmunoprecipitation was performed on late-stationary-phase wild-type cells, and the immunoprecipitates were analyzed for CbpM content by Western blotting. Immunoprecipitations were performed with antibodies raised against the following proteins: lane 1, CbpA; lane 2, CbpM; lane 3, S; lane 4, ClpB; lane 5, ClpA; and lane 6, ClpP. Lane 7, preimmune serum.
|
This research was supported by the Intramural Research Program of the NIH National Cancer Institute Center for Cancer Research.
Published ahead of print on 2 March 2007. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»